KTTA Pasithea Therapeutics Corporation

Pasithea Therapeutics Corp. (Nasdaq: KTTA) (“Pasithea” or the “Company”), a biotechnology company focused on the research and discovery of new and effective treatments for psychiatric and neurological disorders, today announced that Dr. Tiago Reis Marques, Chief Executive Officer, will present at the Benzinga Healthcare Small Cap Conference as follows:

Date:		Thursday, September 30, 2021
Time:		10:10AM ET
Webcast Link:		https://www.benzinga.com/events/small-cap/healthcare/

The presentation will be webcast live at the aforementioned time, and archived for 30 days thereafter, via the Company’s website at www.pasithea.com, under the Investors section.

About Pasithea Therapeutics Corp.

Pasithea Therapeutics Corp. is a biotechnology company focused on the research and discovery of new and effective treatments for psychiatric and neurological disorders. Its biotech operations will focus on developing drugs that target the pathophysiology underlying such disorders, with the goal of developing new pharmacological agents that display significant advantages over conventional therapies with respect to efficacy and tolerability.

The Company’s secondary operations focus on providing business support services to anti-depression clinics in the United Kingdom and in the United States. The Company’s operations in the United Kingdom will involve providing business support services to registered healthcare providers who will assess patients, and if appropriate, administer intravenous infusions of ketamine, and the Company’s operations in the United States will involve providing business support services to entities that furnish similar services.

Pasithea Therapeutics Corp. Company ContactDr. Tiago Reis MarquesChief Executive OfficerE: tiago@pasithea.com

Pasithea Therapeutics Corp. Investor RelationsLisa M. WilsonIn-Site Communications, Inc.T: 212-452-2793E: lwilson@insitecony.com